Emidoxyn 5mg Tablet MD

Interactions

Drug :- aluminum- or magnesium-containing antacids, antidiarrheals adsorbent: Possibly inhibited absorption of oral prochlorperazine amantadine, anticholinergics, antidyskinetics, antihistamines: Possibly intensified anticholinergic adverse effects, increased risk of prochlorperazine-induced hyperpyretic effect.

amphetamines: Decreased stimulant effect of amphetamines, decreased antipsychotic effect of prochlorperazine.

anticonvulsants: Lowered seizure threshold.

antithyroid drugs: Increased risk of agranulocytosis.

apomorphine: Possibly decreased emetic response to apomorphine, additive CNS depression.

appetite suppressants: Possibly antagonized anorectic effect of appetite suppressants.except for phenmetrazine.

astemizole, cisapride, disopyramide, erythromycin, pimozide, probucol, procainamide: Additive QT interval prolongation, increased risk of ventricular tachycardia.

beta blockers: Increased risk of additive hypotensive effects, irreversible retinopathy, arrhythmias, and tardive dyskinesia.

bromocriptine: Decreased effectiveness of bromocriptine.

CNS depressants: Additive CNS depression.

dopamine: Possibly antagonized peripheral vasoconstriction high doses of dopamine.

ephedrine, epinephrine: Decreased vasopressor effects of these drugs.

hepatotoxic drugs: Increased risk of hepatotoxicity.

hypotension-producing drugs: Possibly severe hypotension with syncope.

levodopa: Inhibited antidyskinetic effect of levodopa.

lithium: Reduced absorption of oral prochlorperazine, increased lithium excretion, increased extrapyramidal effects, possibly masking of early symptoms of lithium toxicity. MAO inhibitors, maprotiline, tricyclic antidepressants: Possibly prolonged and intensified anticholinergic and sedative effects, increased antidepressant level, inhibited prochlorperazine metabolism, increased risk of neuroleptic malignant syndrome.

mephentermine: Possibly antagonized antipsychotic effect of prochlorperazine and vasopressor effect of mephentermine.

metrizamide: Increased risk of seizures.

opioid analgesics: Increased risk of CNS and respiratory depression, orthostatic hypotension, severe constipation, urine retention.

ototoxic drugs: Possibly masking of some symptoms of ototoxicity, such as dizziness, tinnitus, and vertigo.

phenytoin: Possibly inhibited phenytoin.

metabolism, increased risk of phenytoin toxicity.

thiazide diuretics: Possibly potentiated hyponatremia and water intoxication.

Activity :- alcohol use: Additive CNS depression.